I am currently pursuing research as a Postdoctoral Research Fellow in the Johns Hopkins University School of Medicine. My research focuses on investigating the interactions of glutamine antagonists and the RAS/Erk signaling pathway in RAS-active sarcomas including RAS-active rhabdomyosarcoma and NF1-mutant malignant peripheral nerve sheath tumor. I recently completed my Ph.D. in Pharmacology in Dr. Krishna Boini's laboratory at University of Houston, TX, USA. My thesis study aimed at understanding the pharmacological contribution of high mobility group box (HMGB)-1 towards driving cigarette smoke induced podocyte injury and glomerulosclerosis. Beyond my thesis study, I have also led studies during my Ph.D. aiming towards comprehending the role of gut microbial metabolite trimethyl-N-oxide (TMAO) towards mediating endothelial injury and initiating atherogenesis. During my M.S.(Pharm.) in Biotechnology, I had gained exposure to in vitro refolding of recombinant human Prolidase to treat organophosphate poisoning- gaining in-depth understanding of protein biochemistry and molecular biology techniques. My long term career objective is to pursue academic research, as an independent scientist, primarily focusing on drug discovery and contributing towards better explaining chronic disease pathogenesis.